MNG56
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.476
- G2M_CHECKPOINT+0.469
- NOTCH_SIGNALING+0.447
- E2F_TARGETS+0.418
- MITOTIC_SPINDLE+0.389
- MTORC1_SIGNALING+0.373
- UV_RESPONSE_DN+0.372
- UNFOLDED_PROTEIN_RESPONSE+0.350
- ANGIOGENESIS+0.341
- HEDGEHOG_SIGNALING+0.335
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.333
- INTERFERON_GAMMA_RESPONSE-0.263
- ESTROGEN_RESPONSE_EARLY-0.197
- KRAS_SIGNALING_DN-0.191
- P53_PATHWAY-0.134
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.129
- ESTROGEN_RESPONSE_LATE-0.105
- XENOBIOTIC_METABOLISM-0.105
- BILE_ACID_METABOLISM-0.101
- FATTY_ACID_METABOLISM-0.099
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5472fa65-a8e2-4593-abd8-e241d1bdec84 | — | — | 0.833 |
| 2 | TCGA-D8-A1JJ-01A-31R-A14M-07 | — | C | 0.809 |
| 3 | TCGA-60-2703-01A-11R-2045-07 | — | cohortSQ1 | 0.799 |
| 4 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.789 |
| 5 | TCGA-D8-A27F-01A-11R-A16F-07 | — | E | 0.787 |
| 6 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.782 |
| 7 | TCGA-AR-A24Q-01A-12R-A169-07 | — | E | 0.781 |
| 8 | MDT-AP-3249 | Med | Medulloblastoma | 0.774 |
| 9 | SRR17866829 | — | — | 0.771 |
| 10 | TCGA-85-7844-01A-11R-2125-07 | — | cohortSQ2 | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.476 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.469 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.447 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.418 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.389 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.373 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.372 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.341 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.335 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.293 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.286 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.242 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.239 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.216 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.204 | Inavolisib | — uncovered |
| HYPOXIA | 0.198 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.182 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.133 | Remibrutinib | — uncovered |